BIOMAT Database Logo BIOMAT Database Logo

Inhibition by SQ 20881 of vasopressor response to angiotensin I in conscious animals. 1973

A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan

UI MeSH Term Description Entries
D008297 Male Males
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001920 Bradykinin A nonapeptide messenger that is enzymatically produced from KALLIDIN in the blood where it is a potent but short-lived agent of arteriolar dilation and increased capillary permeability. Bradykinin is also released from MAST CELLS during asthma attacks, from gut walls as a gastrointestinal vasodilator, from damaged tissues as a pain signal, and may be a neurotransmitter. Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg,Bradykinin Acetate, (9-D-Arg)-Isomer,Bradykinin Diacetate,Bradykinin Hydrochloride,Bradykinin Triacetate,Bradykinin, (1-D-Arg)-Isomer,Bradykinin, (2-D-Pro)-Isomer,Bradykinin, (2-D-Pro-3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (2-D-Pro-7-D-Pro)-Isomer,Bradykinin, (3-D-Pro)-Isomer,Bradykinin, (3-D-Pro-7-D-Pro)-Isomer,Bradykinin, (5-D-Phe)-Isomer,Bradykinin, (5-D-Phe-8-D-Phe)-Isomer,Bradykinin, (6-D-Ser)-Isomer,Bradykinin, (7-D-Pro)-Isomer,Bradykinin, (8-D-Phe)-Isomer,Bradykinin, (9-D-Arg)-Isomer,Arg Pro Pro Gly Phe Ser Pro Phe Arg
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012911 Snakes Limbless REPTILES of the suborder Serpentes. Serpentes,Ophidia,Snake
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Inhibition of brain angiotensin-1 converting enzyme by Bothrops jararaca nonapeptide (SQ 20881) and a prolyl analog (SQ 14225).
June 1978, Journal of neurochemistry,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Inhibition of angiotensin converting enzyme by SQ 14,225 in conscious rabbits.
December 1977, European journal of pharmacology,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Substance P degradation by rat brain peptidases: inhibition by SQ 20881.
January 1979, Biochemical pharmacology,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Accentuated vascular and endocrine response to SQ 20881 in hypertension.
July 1977, The New England journal of medicine,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Use of the angiotensin I antagonist, SQ 20881, for lateralizing renal venous renin activity.
March 1978, Israel journal of medical sciences,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Thermal responses to central angiotensin II, SQ 20881, and dopamine infusions in sheep.
March 1985, The American journal of physiology,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Intrarenal formation of angiotensin II in the rat: interference by Saralasin and SQ 20881.
June 1975, Clinical science and molecular medicine. Supplement,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Angiotensin-converting enzyme inhibitor (SQ 20881) in the diagnosis of renovascular hypertension.
February 1979, Angiology,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
The effect of angiotensin I converting enzyme inhibitor (SQ 20881) on the release of prostaglandins by rabbit kidney, in vivo.
August 1977, British journal of pharmacology,
A Bianchi, and D B Evans, and M Cobb, and M T Peschka, and T R Schaeffer, and R J Laffan
Use of SQ 20881 converting enzyme inhibitor in predicting response to surgery in renovascular hypertension.
January 1982, Angiology,
Copied contents to your clipboard!